The benefits of IL2RA antagonists in heart transplant patients are controversial. We aimed to elucidate the effects of IL2RA antagonists and identify targets that could be better than IL2RA antagonists. By using single-cell RNA sequencing of immune cells at different time points in patients receiving IL2RA antagonists, we identified nineteen types of cells. We revealed higher IL2RA expression in regulatory T cells (Tregs), suggesting that IL2RA antagonists attenuated IL-2-induced Treg activation. CD4_C04_IFNGR1 and CD8_C05_IFITM2 which had more cytotoxic effects, remained elevated at later time points. IFNGR1 was upregulated in these two subtypes, but was not expressed in Treg. Ruxolitinib targeted the pathways of IFNGR1 (JAK1/2) while not affecting the pathway of IL-2-induced Tregs activation (JAK3). Ruxolitinib showed prolonged survival compared to IL2RA mAb-treated mice. Our study provided dynamic changes of immune cells after IL2RA antagonists treatment at single-cell resolution. Ruxolitinib has potential as a new immunoinduction therapy without affecting Treg.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clim.2023.109851 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the causal relationship between inflammatory cytokines and myasthenia gravis: A two-way Mendelian randomization study.
Cytokine
February 2025
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. Electronic address:
Background: Based on previous research, it is well-established that myasthenia gravis (MG) is linked to chronic inflammation. However, the exact nature of the relationship between inflammatory factors and the development of MG remains unclear. Consequently, the objective of this study is to explore whether alterations in the levels of inflammatory factors, as influenced by genetic factors, are associated with the occurrence of MG.
View Article and Find Full Text PDFImpact of induction agents and maintenance immunosuppression on torque teno virus loads and year-one complications after kidney transplantation.
Front Immunol
November 2024
Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany.
Article Synopsis
- Torque teno virus load (TTVL) is being studied as a way to measure immune health in kidney transplant patients, particularly how different medications affect TTVL levels.
- In a study of 134 patients, TTVL levels peaked at 90 days post-transplant and were significantly higher in those who received anti-thymocyte globulin (ATG) compared to interleukin-2 receptor antagonists (IL2-RA).
- Higher TTVL levels may indicate a greater risk of infections for patients, though this trend wasn't statistically significant, suggesting that monitoring TTVL could help manage immunosuppressive therapy post-transplant.
Long-term outcomes of induction immunosuppression for kidney transplant recipients with HIV who have average immunologic risk: An inverse probability treatment weighting analysis.
Am J Transplant
November 2024
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Electronic address:
We analyzed the Scientific Registry of Transplant Recipients (2004-2022) for primary kidney transplant recipients with HIV who had average immunologic risk and were discharged on tacrolimus/mycophenolate mofetil (with or without corticosteroids). Recipients were grouped by induction type: rabbit antithymocyte globulin (r-ATG, n = 688) and human interleukin-2 receptor antagonist (IL2Ra, n = 467). Kaplan-Meier curves were generated to examine recipient and graft survival by induction type.
View Article and Find Full Text PDFOutcomes of Older Primary Kidney Transplant Recipients by Induction Agent and High-risk Viral Discordance Status in the United States.
Transplant Direct
October 2024
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN.
Article Synopsis
- The study investigates how the type of induction therapy and high-risk viral discordance affect outcomes in kidney transplant recipients over the age of 55.
- It analyzes data from over 87,000 transplant cases between 2005 and 2022, focusing on three induction types: rabbit antithymocyte globulin (r-ATG), interleukin-2 receptor antagonist (IL-2RA), and alemtuzumab.
- Results indicate that while induction type didn't impact recipient survival, high-risk Epstein-Barr virus discordance increased mortality, and alemtuzumab was linked to a higher risk of graft loss compared to r-ATG.
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.
Cell Rep Med
October 2024
Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
The clinical use of interleukin-2 (IL-2) for cancer immunotherapy is limited by severe toxicity. Emerging IL-2 therapies with reduced IL-2 receptor alpha (IL-2Rα) binding aim to mitigate toxicity and regulatory T cell (Treg) expansion but have had limited clinical success. Here, we show that IL-2Rα engagement is critical for the anti-tumor activity of systemic IL-2 therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!